Hot Biotech News: 35 upbeat and downbeat stocks
Santarus, Inc. (NASDAQ:SNTS) led biotech movers on Tuesday and marked new 52-week high after the US Food and Drug Administration (FDA) approved its drug Uceris to treat ulcerative colitis.
Viropharma Inc (NASDAQ:VPHM) soared 7.94% after analysts at Bank of America upgraded the stock to a buy rating from a neutral rating.
Nektar Therapeutics (NASDAQ:NKTR) continued to gain yesterday, rallying 7.89% after Lazard Capital Markets initiated coverage on the stock with a buy rating and set a $15.00 price target.
Sangamo Biosciences, Inc. (NASDAQ:SGMO) hit new high and extended five-day winning streak after seeking alpha claimed the company has a chance of joining the ranks of key medical milestones, as it is working on a functional cure for HIV and AIDS, one of the greatest unmet needs in medicine.
ArQule, Inc. (NASDAQ:ARQL) turned green, snapping three-day losing streak after latest Tivantinib failure.
Seattle Genetics, Inc. (NASDAQ:SGEN) is again on the rise after its presentation at the 31st Annual JP Morgan Healthcare Conference January 7, 2013. The stock extended gains and marked new high on Tuesday.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) jumped after a number of retail-investor shareholders charged the U.S. Drug Enforcement Agency of conspiring with Wall Street hedge funds to setback the commercial release of the company’s weight-loss pill Belviq.
Inovio Pharmaceuticals, Inc. (NYSEAMEX:INO) increased 5.21%, extending rally after the company unveiled a plan to test a new vaccine for malaria.
MannKind Corporation (NASDAQ:MNKD) rose 4.82% after KAPITALL reported the stock was at steep discount to its analyst target prices, which may suggest that they were undervalued.
Elsewhere in the biotechnology industry, Celsion Corporation (NASDAQ:CLSN), BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Celgene Corporation (NASDAQ:CELG) broke all-time high while Neuralstem, Inc. (NYSEAMEX:CUR), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) and Peregrine Pharmaceuticals (NASDAQ:PPHM) all rose in a range of 3-4%.
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) edged up after announcing public offering.
More on the upside, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Medivation, Inc.
(NASDAQ:MDVN), Exelixis, Inc. (NASDAQ:EXEL), Dendreon Corporation (NASDAQ:DNDN) and InterMune, Inc. (NASDAQ:ITMN) all rose between 0 and 2%.
On the flip side, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) was one of biggest losers in this industry followed by Zalicus Inc (NASDAQ:ZLCS) with a fall of 7.49%.
Hemispherx BioPharma, Inc (NYSEAMEX:HEB) was under pressure after Pomerantz Grossman Hufford Dahlstrom & Gross LLP has filed a class action lawsuit against the company and certain of its officers.
PDL BioPharma Inc. (NASDAQ:PDLI) lost 4.72% after analysts at Credit Suisse lowered their rating on the stock from Neutral to Underperform and reduced the price target from $6.50 to $6.00.
Novavax, Inc. (NASDAQ:NVAX) declined after The Motley Fool published an article titled “The Trader’s Guide to Flu Profits”.
Amgen, Inc. (NASDAQ:AMGN) extended three-day losing streak after the company signed a nonexclusive license deal with DSM Pharmaceutical Products.
NuPathe Inc (NASDAQ:PATH) continued to fall after a report the company’s experimental migraine headache treatment was getting a second crack at securing Food and Drug Administration marketing approval, 1 and a half year after the agency rejected its initial application.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) were both down about 1.10%.
Sequenom, Inc. (NASDAQ:SQNM), Cell Therapeutics Inc (NASDAQ:CTIC), Biogen Idec Inc.
(NASDAQ:BIIB), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Gilead Sciences, Inc. (NASDAQ:GILD) all fell less than 1%.
Leave a Reply